From November 1992 to December 1997, 25 @entity1 (inoperable or refusing cystectomy) were included in a prospective study to assess the feasibility, tolerance, and curative potential of accelerated radiotherapy (RT) and concomitant @entity900 . Median age was 74 years (range 49-86). Stage distribution was as follows: 1 T1, 10 T2, 8 T3, and 6 T4. Two @entity1 had clinically positive pelvic nodes. The goal was to deliver a total dose of 40 Gy to the whole pelvis and bladder in 4 weeks using a concomitant boost of 20 Gy to the @entity5 or to the whole bladder during the third and fourth weeks (total dose 60 Gy), with daily @entity900 (6 mg/m(2)) before RT for @entity1 with @entity1011 clearance > 50 ml/min. All but one @entity1 completed the RT protocol. Daily @entity900 was successfully delivered in 18 @entity1 . One @entity1 presented with grade III @entity2167 . @entity294 was scored grade III in two and grade IV in two @entity1 . Acute @entity137 was scored grade III in one @entity1 . Posttreatment late effects included bladder grade II and grade III in two @entity1 and one @entity1 , respectively; large bowel grade III in one; urethral grade III in one; and femoral @entity135 in one. Four-year overall and disease-specific survival rates were 23% and 35%, respectively. The latter was 60% for @entity1 with T2 @entity5 . The 4-year actuarial locoregional control rate for all @entity1 was 61%. In summary, accelerated RT and concomitant @entity900 is feasible with acceptable tolerance even in relatively old @entity1 . Although outcome was better for @entity1 with @entity5 , local control and survival rates appeared similar to those of standard RT schedules for a similar @entity1 population.

Invasive bladder carcinoma: a pilot study of conservative treatment with accelerated radiotherapy and concomitant XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity135 :: ('MESH:D006258', 'Disease') :: ['head radionecrosis'] @entity137 :: ('MESH:D064420', 'Disease') :: ['urinary toxicity'] @entity2167 :: ('MESH:D006311', 'Disease') :: ['ototoxicity'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'tumors', 'low-stage tumors'] @entity294 :: ('MESH:D003967', 'Disease') :: ['Diarrhea'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity1011 :: ('MESH:D003404', 'Chemical') :: ['creatinine']
@entity900 :: (MESH:D002945,Chemical) :: ['cisplatin']
